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Management of Device Related Thrombus Post-Left Atrial
Appendage Closure Using WATCHMAN
Yash Patel, Wendy Schell, APN, Sajjad Sabir, MD

Introduction

Case Presentation (cont’)

Discussion

• Atrial fibrillation (AF) is the most prevalent arrythmia
diagnosed in the US. Among patients with AF there is a 5 times
increased risk of stroke. Current stroke preventions regimens
related to AF include oral anticoagulants such as Warfarin or
more recently introduced factor II/Xa inhibitors5,3.
• The PROTECT AF and PREVAIL trials showed the benefits of
WATCHMAN device as an alternate therapy in patients with AF
and contraindications to current stroke regimens for
cardioembolic stroke prevention2.
• One of the major complications with WATCHMAN left atrial
appendage closure (LAAC) is device related thrombus (DRT).
Currently there are no published recommendations on
management of DRT post-LAA closure using WATCHMAN
device6.
• We report the management of a patient with AF and GI bleed
who underwent left atrial appendage occlusion using
WATCHMAN complicated by device related thrombus.

• She was admitted and started on intravenous (IV) heparin
infusion.
• After consulting with cardiothoracic surgery to consider
surgical removal of the thrombus, decision was made to treat
her conservatively using IV heparin followed by Coumadin with
repeat TEE few weeks later to re-assess the thrombus burden.
• A follow up TEE a month later showed a significant reduction in
size of the thrombus.
• She was continued on warfarin which was well tolerated and a
TEE was repeated 2 months later that showed resolution of the
thrombus.

• Typically, LAAC devices require a short-term course of OAC for
a few weeks to months during device endothelization but in
some patients complete endothelization may not occur which
can increase the risk of peri-device leak and device related
thrombus6.
• The recommended post implant management by PROTECT AF
trail includes aspirin and warfarin to achieve INR of 2-4 until
45-day visit.
• Risk factors associated with DRT have been examined by very
few studies which include: left ventricular ejection fraction of
<40%, pre existing LAA thrombus, LAA peak emptying velocity,
smoking and a higher CHA2DS2-VASc score4.
• A multicenter study with 214 patients proved NOACs to be a
feasible alternate regimen to warfarin to prevent DRT and
thromboembolic complications post LAAC1.
• In this report, dabigatran, a NOAC was used post procedurally
to prevent device associated thrombus but given the patients
risk factors of high CHADS-VASc score we believe that the
continued half dose was possibly inadequate for DRT
prevention. Additionally the patient was also not taking
aspirin during the critical first few week's post device implant.
• After the failed approach with dabigatran and aspirin, and in
favor of a more conservative approach to avoid LAA
amputation, we opted for inpatient IV heparin and continued
warfarin for 1 year which led to resolution of the thrombus.
• Further research needs to go into the duration and choice of
anticoagulation for management of device related thrombus.

Case Presentation
• A 77-year-old female with paroxysmal AF was referred to our
institution for LAAC. CHA2DS2-VASc and HASBLED scores
were 4.
• Appropriately treated with coumadin but was switched to
dabigatran secondary to labile INR.
• Management complicated by gastro-intestinal (GI) bleed →
referred for LAAC evaluation.
• A trans-esophageal echocardiogram (TEE) found the
appendage anatomy suitable for LAAC
• Successfully underwent a 33 mm WATCHMAN implant and
was discharged on full dose dabigatran along with aspirin.
• However, patient’s cardiologist had reduced it to half dose
dabigatran due to concern for GI bleed. Additionally, the
patient stopped taking aspirin.
• At a 45 day follow up TEE demonstrated a device associated
thrombus measuring 3.6 cm x 2.2 cm covering the entire
WATCHMAN device surface facing the left atrium. No
significant flow around the device noted.

Figure 1: Device associated thrombus (red arrow)
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